معرفی
Professor Philip Beer is a physician scientist with a focus on precision medicine in oncology drug development and patient stratification. His current roles include heading research and translational medicine at Step Pharma and serving as an honorary consultant at NHS Greater Glasgow and Clyde. He also holds honorary research positions at the Wellcome Trust Sanger Institute and the Mayo Clinic.
- Educational background: BMedSci, BM.BS, PhD
- Professional memberships: International Cancer Genome Consortium (ICGC), Friends of Cancer Research Tumor Mutational Burden Working Group
Philip Beer's research emphasizes cancer genomics and advanced preclinical modeling. His work explores genotype-phenotype correlations in haematological cancers and aims to democratize biomarker profiling in routine oncology practice. Recent projects include benchmarking tumor mutational burden and harmonizing homologous recombination deficiency assessments.
His publications span topics such as molecular profiling, genomic subtyping, and HDAC6 inhibition in precision oncology. Articles highlight his efforts to integrate computational solutions with clinical workflows and define clinical genomic landscapes.
- Member of the Royal College of Physicians (MRCP)
- Fellow of the Royal College of Pathologists (FRCPath)
Beer leads the British In Vitro Diagnostic Association's Genomics Working Group and contributes to initiatives like the ARGO and PCAWG projects. His cross-sector roles bridge academia, healthcare, and biotech to accelerate oncology drug development.
